Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Genzyme General discontinues U.S. development of Sepracoat

Jan. 15, 1998

New class of glucocorticoids with an improved pharmacological profile

Jan. 15, 1998

IMPDH inhibitor VX-497 advances to clinical trials

Jan. 14, 1998

OrthoLogic makes equity investment in Chrysalis; acquires rights to new peptide

Jan. 13, 1998

Cellegy acquires Anogesic

Jan. 13, 1998

ADCON-L submitted to regulatory authorities

Jan. 9, 1998

ABX-IL-8 slated to enter clinical testing

Jan. 8, 1998

NDA filed for betamethasone mousse

Jan. 7, 1998

Biomatrix's Hyalform approved in additional markets; PMA resubmission planned in U.S.

Jan. 5, 1998

Structurally distinct vitamin D analogues from Leo

Jan. 5, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...